(a) The following words and terms when used
in this section, shall have the following meanings, unless the context clearly
indicates otherwise:
"Acute pain" means the pain, whether resulting from disease,
accidental or intentional trauma, or other cause, that the practitioner
reasonably expects to last only a short period of time. "Acute pain" does not
include chronic pain, pain being treated as part of cancer care, hospice or
other end of life care, or pain being treated as part of palliative
care.
"Chronic pain" means pain that persists or recurs for more
than three months.
"Initial prescription" means a prescription issued to a
patient who:
1. Has never previously
been issued a prescription for the drug or its pharmaceutical equivalent;
or
2. Was previously issued a
prescription for, or used or was administered the drug or its pharmaceutical
equivalent, and the date on which the current prescription is being issued is
more than one year after the date the patient last used or was administered the
drug or its equivalent. When determining whether a patient was previously
issued a prescription for, or used or was administered a drug or its
pharmaceutical equivalent, the practitioner shall consult with the patient,
review prescription monitoring information, and, to the extent it is available
to the practitioner, review the patient's medical record.
"Opioid antidote" means any drug, regardless of dosage amount
or method of administration, that has been approved by the United States Food
and Drug Administration (FDA) for the treatment of an opioid overdose. "Opioid
antidote" includes, but is not limited to, naloxone hydrochloride, in any
dosage amount, that is administered through nasal spray or any other
FDA-approved means or methods.
"Palliative care" means care provided to an individual
suffering from an incurable progressive illness that is expected to end in
death, which is designed to decrease the severity of pain, suffering, and other
distressing symptoms, and the expected outcome of which is to enable the
individual to experience an improved quality of life.
"Practitioner" means an individual currently licensed,
registered, or otherwise authorized to prescribe drugs in the course of
professional practice, to include a physician, a podiatrist, a physician
assistant, and a certified nurse midwife, acting within the scope of practice
of his or her professional license or certification.
"Treatment plan" means a memorialization of the objectives by
which treatment success is to be evaluated, including, when treating the
patient for pain, the specific objectives for pain relief and improved physical
and psychological function and any further diagnostic evaluations or other
treatments planned, with particular focus on determining the cause of the
patient's pain, and when treating chronic pain, the terms of the pain
management agreement.
(b) When initiating the prescribing of, the
dispensing of, or the administration of controlled dangerous substances, a
practitioner shall:
1. Take a thorough medical
history of the patient, which reflects the nature, frequency, and severity of
any pain, the patient's history of substance use or abuse, and the patient's
experience with non-opioid medication and non-pharmacological pain management
approaches;
2. Conduct a physical
examination appropriate to the standard of care relating to the patient's
condition, including an assessment of physical and psychological function, and
an evaluation of underlying or coexisting physical and psychological diseases
or conditions, including anxiety and depression;
3. Make a reasonable effort to obtain and
review the patient's medical record;
4. Determine, when treating the patient's
pain, if the patient was previously issued a prescription for, used, or was
administered a drug or its pharmaceutical equivalent. The practitioner may make
this determination by reviewing the patient's medical record, if available,
reviewing the patient's prescription monitoring information, or consulting with
the patient;
5. Access relevant
prescription monitoring information as maintained by the Prescription
Monitoring Program (PMP) pursuant to
N.J.S.A.
45:1-46.1 and consider that information in
accordance with N.J.A.C. 13:45A-35;
6. Develop a treatment plan; and
7. Prepare a medical record, which includes
the:
i. Medical history;
ii. Findings on examination;
iii. Relevant PMP data;
iv. Efforts made to obtain the patient's
medical records;
v. Treatment plan;
and
vi. Medications prescribed,
dispensed, or administered, including:
(1) The
complete name of the controlled substance;
(2) The dosage, strength, and quantity of the
controlled substance; and
(3) The
instructions as to frequency of use.
(c) With respect to Schedule II controlled
dangerous substances, unless the requirements of this subsection are met or the
prescribing of opioids is subject to limitations as set forth at (g) below, a
practitioner may authorize a quantity, not to exceed a 30-day supply, which
shall be at the lowest effective dose as determined by the directed dosage and
frequency of dosage. The prescribing of opioids in any schedule is subject to
limitations as set forth at (g) below.
1.
Notwithstanding the 30-day supply limitation, a practitioner may prescribe the
use of an implantable infusion pump that is utilized to achieve pain management
for patients suffering from cancer, intractable pain, or terminal illness. A
prescription for such an implantable infusion pump may provide up to a 90-day
supply, as long as the physician evaluates and documents the patient's
continued need at least every 30 days; and
2. Notwithstanding the 30-day supply
limitation, a physician may prescribe multiple prescriptions authorizing a
patient to receive a total of up to a 90-day supply of a Schedule II controlled
dangerous substance provided that:
i. Each
separate prescription is issued for a legitimate medical purpose by the
practitioner acting in the usual course of professional practice;
ii. The practitioner provides written
instructions on each prescription, other than the first prescription if it is
to be filled immediately, indicating the earliest date on which a pharmacy may
fill each prescription;
iii. The
practitioner determines that providing the patient with multiple prescriptions
in this manner does not create an undue risk of diversion or abuse;
iv. The practitioner evaluates the benefits
and harms of opioid therapy when treating a patient for pain, and determines
that clinically meaningful improvement in pain and function outweigh the risks
to patient safety; and
v. The
practitioner complies with all other applicable State and Federal laws and
regulations.
(d) Prior to issuing an initial prescription
for a Schedule II controlled dangerous substance or any opioid drug in the
course of treatment for acute pain, a practitioner shall discuss with the
patient, or the patient's parent or guardian if the patient is under 18 years
of age and is not an emancipated minor, the reasons why the medication is being
prescribed, the treatment plan, including the objectives to be accomplished
with the medication, the possible alternative treatments, and the risks
associated with the medication. With respect to opioid drugs, the discussion
shall include, but not be limited to, the risks of addiction, including that
opioids are highly addictive, even when taken as prescribed and used as
directed, physical or psychological dependence, and overdose associated with
opioid drugs and the danger of taking opioid drugs with alcohol,
benzodiazepines, and other central nervous system depressants, and requirements
for proper storage and disposal.
1. If the
patient is under 18 years of age and is not an emancipated minor, the
practitioner shall have the discussion required under (d) above prior to the
issuance of each subsequent prescription for any opioid drug that is a Schedule
II controlled dangerous substance.
2. The practitioner shall reiterate the
discussion required in (d) above prior to issuing a prescription at the outset
of a course of treatment for chronic pain for a Schedule II controlled
dangerous substance or any opioid drug.
3. The practitioner shall include a note in
the patient record that the required discussion(s) took
place.
(e) Prior to the
commencement of an ongoing course of treatment for chronic pain with a Schedule
II controlled dangerous substance or any opioid, the practitioner shall enter
into a pain management agreement with the patient. The pain management
agreement shall be a written contract or agreement that is executed between a
practitioner and a patient, that is signed and dated prior to the commencement
of an ongoing course of treatment for chronic pain using a Schedule II
controlled dangerous substance or any opioid drug, and which shall:
1. Document the understanding of both the
practitioner and the patient regarding the patient's treatment plan, taking
into account the patient's history since being initiated on opioids, current
progress toward objectives in the treatment plan, and modified treatment
objectives, as appropriate, and in accordance with the standard of
care;
2. Establish the patient's
rights in association with treatment, and the patient's obligations in relation
to the responsible use, discontinuation of use, and storage and disposal of
Schedule II controlled dangerous substances and any opioid drugs, including any
restrictions on the refill or acceptance of such prescriptions from
practitioners and other prescribers;
3. Identify the specific medications and
other modes of treatment, including physical therapy or exercise, relaxation,
or psychological counseling, that are included as part of the treatment
plan;
4. Specify the measures the
practitioner may employ to monitor the patient's compliance including, but not
limited to, random specimen screens and pill counts; and
5. Delineate the process for terminating the
agreement, including the consequences if the practitioner has reason to believe
that the patient is not complying with the terms of the
agreement.
(f) When
controlled dangerous substances are continuously prescribed for management of
chronic pain, the practitioner shall:
1.
Review, at a minimum of every three months, the course of treatment, any new
information about the etiology of the pain, and the patient's progress toward
treatment objectives, and discuss with the patient the course of treatment and
progress toward objectives in the treatment plan and document the results of
that review;
2. Assess the patient
prior to issuing each prescription to determine whether the patient is
experiencing problems associated with physical and psychological dependence,
and document the results of that assessment;
3. Make periodic reasonable efforts, unless
clinically contraindicated, to either stop the use of the controlled dangerous
substance, taper the dosage, try other drugs, such as nonsteroidal
anti-inflammatories, or utilize alternative treatment modalities in an effort
to reduce the potential for abuse or the development of physical or
psychological dependence, and document, with specificity, the efforts
undertaken;
4. Discontinue (through
tapering, if necessary) opioid therapy, in accordance with the standard of care
if there is insufficient clinically meaningful improvement in pain and
function;
5. Access relevant
prescription monitoring information as maintained by the Prescription
Monitoring Program (PMP) pursuant to
N.J.S.A.
45:1-46.1 and consider that information in
accordance with N.J.A.C. 13:45A-35;
6. Monitor compliance with the pain
management agreement and continue to assess whether the patient's improvement
in pain and function outweigh risks to patient safety;
7. Monitor compliance with any
recommendations that the patient seek a referral;
8. Discuss with the patient any breaches that
reflect that the patient is not taking the drugs as prescribed, is taking
illicit drugs, or is taking other prescribed drugs without informing the
practitioner, and document within the patient record the plan after that
discussion;
9. Conduct random urine
screens at least once every 12 months;
10. Advise the patient, or the patient's
parent or guardian if the patient is under 18 years of age and is not an
emancipated minor, of the availability of an opioid antidote; and
11. Refer the patient to a pain management or
addiction specialist for independent evaluation or treatment if the patient is
not attaining clinically meaningful improvement in pain and function, in
accordance with the treatment plan.
(g) A practitioner shall not issue an initial
prescription for an opioid drug for treatment of acute pain in a quantity
exceeding a five-day supply as determined by the directed dosage and frequency
of dosage. The initial prescription shall be for the lowest effective dose of
an immediate-release opioid drug. A practitioner shall not issue an initial
prescription for an opioid drug that is for an extended-release or long-acting
opioid. No less than four days after issuing the initial prescription, upon
request of the patient, a practitioner may issue a subsequent prescription for
an opioid drug for the continued treatment of acute pain associated with the
condition that necessitated the initial prescription provided the following
conditions are met:
1. The practitioner
consults (in person, via telephone, or other means of direct communication)
with the patient;
2. After the
consultation with the patient and consideration of the treatment plan, the
practitioner, in the exercise of his or her professional judgment, determines
that an additional days' supply of the prescribed opioid drug is necessary and
appropriate to the patient's treatment needs and does not present an undue risk
of abuse, addiction, or diversion and is consistent with the treatment
plan;
3. The practitioner documents
the rationale for the authorization in the patient record;
4. The subsequent prescription for an
additional days' supply of the prescribed opioid drug is tailored to the
patient's expected need at the stage of recovery, as determined under (g)2
above and any subsequent prescription for an additional days' supply shall not
exceed a 30-day supply, unless authorized pursuant to (c) above.
5. When a patient is prescribed a course of
opioid treatment that is to last more than 35 days, the practitioner shall
discuss with the patient an exit strategy consistent with the standard of care
for the discontinuation of opioids in the event they are not providing
clinically meaningful improvement in pain or function, and shall modify the
treatment plan to include the exit strategy; and
6. The practitioner shall include a note in
the record that the exit strategy discussion required at (g)5 above, took
place.
(h) When a
practitioner issues an initial prescription for an opioid drug for the
treatment of acute pain, the practitioner shall so indicate it on the
prescription.
(i) Except as
provided at (i)1 below, when a practitioner issues a patient a prescription for
an opioid drug that is a controlled dangerous substance, the practitioner shall
also issue the patient a prescription for an opioid antidote when the patient
has a history of substance use disorder, the prescription for the opioid drug
is for a daily dose of more than 90 morphine milligram equivalents, or the
patient holds a current, valid prescription for a benzodiazepine drug that is a
Schedule III or Schedule IV controlled dangerous substance.
1. A practitioner shall not be required to
issue more than one prescription for an opioid antidote to a patient per
year.
2. Nothing at (i)1 above
shall be construed to prohibit a practitioner from issuing additional
prescriptions for an opioid antidote to a patient upon the patient's request or
when the practitioner determines there is a clinical or practical need for the
additional prescription.
(j) The requirements for prescribing
controlled dangerous substances set forth at (d) through (i) above shall not
apply to a prescription for a patient who is currently in active treatment for
cancer, receiving hospice care from a licensed hospice, receiving palliative
care, or is a resident of a longterm care facility, or to any medications that
are being prescribed for use in the treatment of substance abuse or opioid
dependence.
(k) Nothing in (g)
above shall be construed to limit a practitioner's professional judgment to
authorize a subsequent prescription for an opioid drug in a quantity consistent
with (g)4 above for the continued treatment of acute pain associated with the
condition that necessitated the initial prescription.